首页> 美国卫生研究院文献>Journal of Virology >Infectious Clones and Vectors Derived from Adeno-Associated Virus (AAV) Serotypes Other Than AAV Type 2
【2h】

Infectious Clones and Vectors Derived from Adeno-Associated Virus (AAV) Serotypes Other Than AAV Type 2

机译:除2型AAV以外的腺相关病毒(AAV)血清型衍生的感染性克隆和载体

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Adeno-associated viruses (AAVs) are single-stranded dependent parvoviruses being developed as transducing vectors. Although at least five serotypes exist (AAV types 1 to 5 [AAV1 to -5]), only AAV2, AAV3, and AAV4 have been sequenced, and the vectors in use were almost all derived from AAV2. Here we report the cloning and sequencing of a second AAV3 genome and a new AAV serotype designated AAV6 that is related to AAV1. AAV2, AAV3, and AAV6 were 82% identical at the nucleotide sequence level, and AAV4 was 75 to 78% identical to these AAVs. Significant sequence variation was noted in portions of the capsid proteins that presumably are responsible for serotype-specific functions. Vectors produced from AAV3 and AAV6 differed from AAV2 vectors in host range and serologic reactivity. The AAV3 and AAV6 vector serotypes were able to transduce cells in the presence of serum from animals previously exposed to AAV2 vectors. Our results suggest that vectors based on alternative AAV serotypes will have advantages over existing AAV2 vectors, including the transduction of different cell types, and resistance to neutralizing antibodies against AAV2. This could be especially important for gene therapy, as significant immunity against AAV2 exists in human populations and many protocols will likely require multiple vector doses.
机译:腺相关病毒(AAV)是单链依赖性细小病毒,已被开发为转导载体。尽管存在至少五种血清型(AAV类型1至5 [AAV1至-5]),但仅对AAV2,AAV3和AAV4进行了测序,使用的载体几乎全部来自AAV2。在这里,我们报告了第二个AAV3基因组和与AAV1相关的称为AAV6的新AAV血清型的克隆和测序。 AAV2,AAV3和AAV6在核苷酸序列水平上的一致性为82%,而AAV4与这些AAV的一致性为75%至78%。在衣壳蛋白的某些部分中发现了明显的序列变异,这些部分可能与血清型特异性功能有关。由AAV3和AAV6产生的载体在宿主范围和血清反应性方面与AAV2载体不同。 AAV3和AAV6载体血清型能够在先前暴露于AAV2载体的动物的血清中转导细胞。我们的结果表明,基于替代AAV血清型的载体将比现有AAV2载体具有优势,包括不同细胞类型的转导以及对中和AAV2抗体的抗性。这对于基因治疗可能尤其重要,因为在人群中存在针对AAV2的显着免疫力,许多方案可能需要多次载体剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号